| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/19/2013 | CN102283873B Ultrasonic extraction method for saponin of Aralia elata blade |
| 06/19/2013 | CN102274254B Preparation method of alligator alternanthera effective fraction extract |
| 06/19/2013 | CN102260698B PTA-linker-thanatin fusion protein expressed in escherichia coli, and anticancer research thereof |
| 06/19/2013 | CN102250342B PEG/mPEG (Polyethylene Glycol) multi-carboxyl chemical modifying agent connected with citric acid, preparation method and application thereof in modification of toluylene compound |
| 06/19/2013 | CN102240399B Application of siniperca chuatsi ISKNV (Infectious Spleen and Kidney Necrosis Virus) ORF093 protein |
| 06/19/2013 | CN102178956B Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound |
| 06/19/2013 | CN102106856B Entecavir medicinal composition and preparation method thereof |
| 06/19/2013 | CN102046172B Pharmaceutical compositions containing a crystalline form of posaconazole |
| 06/19/2013 | CN101970462B Cyclic compound and salt thereof |
| 06/19/2013 | CN101967108B Methacycline derivative |
| 06/19/2013 | CN101945866B Aminothiazoles and their uses |
| 06/19/2013 | CN101914533B Interfering rna duplex having blunt-ends and 3'-modifications |
| 06/19/2013 | CN101914134B Linear epitope minimum motif peptide of human papilloma virus type 58 E7 protein |
| 06/19/2013 | CN101910159B Process for production of heterocycle-substituted pyridine derivative |
| 06/19/2013 | CN101838611B Recombinant plasmodium for expressing exogenous gene and application thereof |
| 06/19/2013 | CN101823990B Amino-acid ester dithiocarbamic acid ester compound as well as preparation method and application thereof |
| 06/19/2013 | CN101773468B Zanamivir nasal nanometer suspension and preparation method thereof |
| 06/19/2013 | CN101754966B 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors |
| 06/19/2013 | CN101744823B Solid dispersion of dihydropyrimidine compounds and preparation thereof for medical purpose |
| 06/19/2013 | CN101701245B Method for separating SARS coronavirus main proteinase inhibitor from traditional Chinese medicine |
| 06/19/2013 | CN101687870B Nitrogenous heterocyclic compounds, preparation thereof and use thereof as antibacterial medicaments |
| 06/19/2013 | CN101574333B Allitride composition and method for preparing drop therewith for treating nasal cavity infected by microbes and application thereof |
| 06/19/2013 | CN101460519B Human binding molecules having killing activity against staphylococci and uses thereof |
| 06/19/2013 | CN101432428B Recombinant human interferon-like proteins |
| 06/19/2013 | CN101426528B Methods of using antibodies against human il-22 |
| 06/19/2013 | CN101374509B Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| 06/19/2013 | CN101353373B Synthetic peptide vaccines for foot-and-mouth disease |
| 06/19/2013 | CN101318016B Multivalent human-bovine rotavirus vaccine |
| 06/19/2013 | CN101107234B HIV inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives |
| 06/18/2013 | USRE44302 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use |
| 06/18/2013 | US8466261 Therapeutic using a bispecific antibody |
| 06/18/2013 | US8466127 Pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system |
| 06/18/2013 | US8466102 Antimicrobial cationic peptides and formulations thereof |
| 06/18/2013 | US8465777 Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| 06/18/2013 | US8465750 Staphylococcus aureus proteins and nucleic acids |
| 06/18/2013 | US8464706 Drug delivery apparatus |
| 06/18/2013 | CA2561245C Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| 06/18/2013 | CA2459348C Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 06/18/2013 | CA2422002C Vaccine |
| 06/18/2013 | CA2415187C Dna vaccines encoding hiv accessory proteins |
| 06/13/2013 | WO2013086533A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | WO2013086467A1 Benzotriazine oxides as drugs targeting mycobacterium tuberculosis |
| 06/13/2013 | WO2013086331A1 High efficiency di-nucleotide cyclase |
| 06/13/2013 | WO2013086292A1 Glucagon formulations |
| 06/13/2013 | WO2013086181A1 Biocidal compositions and methods of using the same |
| 06/13/2013 | WO2013086003A1 Antimicrobial agent, bacterial strain, biosynthesis, and methods of use |
| 06/13/2013 | WO2013085824A1 Small molecule anti-fibrotic compounds and uses thereof |
| 06/13/2013 | WO2013085550A2 V1v2 immunogens |
| 06/13/2013 | WO2013085152A1 Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
| 06/13/2013 | WO2013085017A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013085016A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013084165A1 Hcv polymerase inhibitors |
| 06/13/2013 | WO2013084130A1 Multicomponent crystalline system of voriconazole with fumaric acid |
| 06/13/2013 | WO2013083724A1 Beta-o/s/n fatty acid based compounds as antibacterial and antiprotozoal agents |
| 06/13/2013 | WO2013083095A1 Novel antibiotic preparation method and platform system based on same |
| 06/13/2013 | WO2013083036A1 Porcine circovirus type-2 subunit vaccine |
| 06/13/2013 | WO2013055825A3 Guanidinyl-substituted polyamides useful for treating human papilloma virus |
| 06/13/2013 | WO2013020024A3 Maleimide compounds and methods of treatment |
| 06/13/2013 | WO2013009910A3 Eosinophil peroxidase compositions and methods of their use |
| 06/13/2013 | US20130150316 Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
| 06/13/2013 | US20130150311 Mixed poloxamer excipients |
| 06/13/2013 | US20130150287 RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME |
| 06/13/2013 | US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents |
| 06/13/2013 | US20130149379 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 06/13/2013 | US20130149334 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/13/2013 | US20130149324 Therapeutic tb vaccine |
| 06/13/2013 | US20130149283 Methods and compositions for treating hepatitis c virus |
| 06/13/2013 | CA2858716A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | CA2858561A1 Biocidal compositions and methods of using the same |
| 06/13/2013 | CA2858347A1 V1v2 immunogens |
| 06/13/2013 | CA2858316A1 Multicomponent crystalline system of voriconazole with fumaric acid |
| 06/13/2013 | CA2858164A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | CA2857976A1 Novel antibiotic preparation method and platform system based on same |
| 06/13/2013 | CA2855351A1 Novel pyrrole derivatives |
| 06/12/2013 | EP2602260A1 Process for preparing compound having hiv integrase inhibitory activity |
| 06/12/2013 | EP2602253A1 Crystal of anti-bacterial compound |
| 06/12/2013 | EP2602252A1 Pyridazine derivatives and use thereof as medicaments for treating microrna viral infection |
| 06/12/2013 | EP2602248A1 Novel pyrrole compounds |
| 06/12/2013 | EP2601967A1 Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids |
| 06/12/2013 | EP2601957A1 Immunological function enhancing agent |
| 06/12/2013 | EP2601947A1 Fixed-dose combination for treatment of helicobacter pylori associated diseases |
| 06/12/2013 | EP2601941A1 Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
| 06/12/2013 | EP2601938A1 Pharmaceutical compositions for the treatment of Helicobacter pylori associated diseases |
| 06/12/2013 | EP2601219A2 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 06/12/2013 | EP2601205A2 Guanine nucleotide derivatives for treating bacterial infections |
| 06/12/2013 | EP2601193A1 Compounds with antibacterial activity against clostridium |
| 06/12/2013 | EP2601188A1 Hepatitis c virus inhibitors |
| 06/12/2013 | EP2601174A1 Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| 06/12/2013 | EP2600892A2 Modified infectious laryngotracheitis virus (iltv) and uses thereof |
| 06/12/2013 | EP2600883A1 Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
| 06/12/2013 | EP2600872A1 Fused-imidazoyl compounds useful as antimicrobial agents |
| 06/12/2013 | EP2600869A1 Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine |
| 06/12/2013 | EP2600868A1 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent |
| 06/12/2013 | EP2600842A1 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases |
| 06/12/2013 | EP2600835A1 Combinations of hepatitis c virus inhibitors |
| 06/12/2013 | EP2475657B1 5-alkinylthien-2-ylcarboxylic acids as inhibitors of flaviviridae viruses |
| 06/12/2013 | EP2178869B1 Indole compounds as an inhibitor of cellular necrosis |
| 06/12/2013 | CN1921885B Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient |
| 06/12/2013 | CN1668305B Microbicidal pyrimidine or triazine for preventing sexual HIV transmission |
| 06/12/2013 | CN1525857B Method for regulation of gene expression in eukaryotic cells using nordihydroguaiaretic acid derivatives |